Three Rivers Pharmaceuticals Announces Dismissal of ICN Appeal

Cranberry Township, Pennsylvania, June 4, 2004 Three Rivers Pharmaceuticals, LLC today announced that the appeal filed by Valeant Pharmaceuticals International, formally ICN Pharmaceuticals Inc., scheduled for oral arguments next week in Washington, D.C. has been dismissed.

The dismissal came at ICNs request. Three Rivers obtained summary judgment of non-infringement in the United States District Court for the Central District of California in July 2003.

Three Rivers Pharmaceuticals in conjunction with its marketing partner Par Pharmaceutical (PRX) commercially launched Ribasphere™ (Ribavirin capsules) 200 mg at risk in April 2004 after receiving FDA approval.

The dismissal of the appeal by ICN validates our position that the case was without merit, said Donald J. Kerrish, President and CEO of Three Rivers. The dismissal by ICN eliminates the risk of further litigation regarding this case.

Ribasphere™ (Ribavirin capsules) 200 mg is used in combination with interferon alpha to treat Hepatitis C. Hepatitis C affects as many as four million Americans.

Three Rivers Pharmaceuticals, LLC is a privately owned generic drug manufacturing company located in Cranberry Township, Pennsylvania, just north of Pittsburgh.

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top